The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova A.S.

Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain

Authors:

Chukanova E.I., Chukanova A.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9): 39‑45

DOI: 10.17116/jnevro201911909139

Read: 10319 times

Download PDF (RU)
Contact the author
Table of contents

EFFICACY AND SAFETY OF THE DRUG MEXIDOL FORTE 250 AS PART OF SEQUENTIAL THERAPY IN PATIENTS WITH CHRONIC ISCHEMIA OF THE BRAIN
EFFICACY AND SAFETY OF THE DRUG MEXIDOL FORTE 250 AS PART OF SEQUENTIAL THERAPY IN PATIENTS WITH CHRONIC ISCHEMIA OF THE BRAIN

To cite this article:

Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39‑45. (In Russ.)
https://doi.org/10.17116/jnevro201911909139

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The effect of Mexi­dol on the level of neurogenesis markers in acute cere­brovascular acci­dent in the expe­riment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45
Asso­ciations between the gut microbiota-derived meta­bolites with the para­meters of 24-hour ambu­latory blood pressure moni­toring in patients on maintenance hemo­dialysis. Russian Journal of Preventive Medi­cine. 2025;(3):96-102
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
The influence of demo­graphic factors and major como­rbidities on serum circulating regu­latory microRNAs in patients with coro­nary artery athe­rosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182
Abstract:

Objective. To study the efficacy and safety of mexidol dripped intravenously (500 mg once a day) in the form of infusions for 14 days, followed by oral administration of mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days, in treatment of chronic brain ischemia in patients with hypertension and atherosclerosis. Material and methods. The open observation program included 60 patients with an established diagnosis of chronic brain ischemia confirmed by neuroimaging methods. Results and conclusion. The results of the study show the high efficacy and safety of sequential therapy (injections followed by tablets of mexidol FORTE 250). The treatment improves emotional and cognitive status, decreases motor disorders and severity of subjective manifestations. High adherence of patients to the therapy is shown.

Keywords:

chronic cerebrovascular disease
arterial hypertension
atherosclerosis
ethylmethylhydroxypyridine succinate
mexidol
cognitive impairment

Authors:

Chukanova E.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Moskva

Chukanova A.S.

Close metadata

References:

  1. Stroke. Guide for doctors. Edited by Stakhovskaya L.V., Kotov S.V. 2-e ed., rev. and extra. M.: OOO «Medical informative agency»; 2018. (In Russ.)
  2. Stroke: modern technologies of diagnosis and treatment. Manual for physicians. Ed. by Piradov M.A., Tanashyan M.M., Maksimova M.Yu. 3rd rev. M.: Medpress-inform; 2018. (In Russ.)
  3. Levin OS. Diagnosis and treatment of dyscirculatory encephalopathy. Method. benefit. M. 2010. (In Russ.)
  4. Chukanova EI, Chukanova AS. Separate mechanisms of pathogenesis of formation of cerebral circulation insufficiency. Pharmateca (Cardiology/Neurology). 2014;13(286):14-20. (In Russ.)
  5. Gusev EI, Skvortsova VI. Cerebral ischemia. M.: Medicine; 2001.
  6. Gomazkov OA. Neurotrophic and growth factors of the brain: regulatory specificity and therapeutic potential. Advances in Physiological Sciences. 2005;36(2):1-25.
  7. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173-185.
  8. Fedin AI. Selected lectures on outpatient neurology. M.: LLC «AST 345»; 2013.
  9. Sokolova LP. Documentee cognitive disorders. M.: LLC «AST 345»; 2016.
  10. Chukanova EI, Chukanova AS. Chronic brain ischemia (risk factors, pathogenesis, clinic, treatment). Methodical recommendation. M. 2015. (In Russ.)
  11. Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinic, treatment). M.: Act 345; 2018. (In Russ.)
  12. Kadjikov AS, Manvelov LS, Shahparonova NV. Chronic vascular diseases of the brain encephalopathy. Guide for doctors. 3rd edition, revised and expanded. M.: GEOTAR-Media; 2014. (In Russ.)
  13. Tanashyan MM, Ladoga OV, Antonova KV. Cerebrovascular pathology, metabolic syndrome and diabetes mellitus: management tactics. M.: Media Sphera; 2014. (In Russ.)
  14. Tanashyan MM. Vascular diseases of the brain and metabolic syndrome. Guide for doctors. M.: LLC «AST 345»; 2017. (In Russ.)
  15. Duma SN. Possibilities of antioxidant therapy in asthenia and cognitive deficits in elderly patients with chronic brain ischemia. Therapeutic Archive. 2013;12:100-105. (In Russ.)
  16. Drozdova TV, Fitmova OA, Fitmova AA. The Role of Mexidol in the treatment of moderate cognitive disorders in the framework of the manifestations of chronic cerebrovascular insufficiency. Pharmateca. 2012;14:97-103.
  17. Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases on the background of metabolic syndrome: new approaches to treatment. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(11):21-26.
  18. Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Clinical efficacy and antioxidant activity of Mexidol in chronic cerebrovascular diseases. Atmosphere. Nervous disease. 2006;1:61-64. (In Russ.)
  19. Chukanova EI, Chukanova AS, Mamaeva HI. The results of the study of the efficacy and safety of Mexidol in patients with chronic brain ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(2):71-74. (In Russ.)
  20. Lebedeva NV, Khrapova EV, Fedorova TN. The impact of the new Patriotic antioxidant emoxipin on the state of processes of lipid peroxidation in the treatment of patients with transient disorders of cerebral circulation and discirkulatornaya encephalopathy. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 1991;91(7):79-82. (In Russ.)
  21. Maksimova MYu, Tanashyan MM, Smirnova IN. Treatment of ischemic stroke. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;115(4):126-129. (In Russ.)
  22. Voronina TA. Mexidol: basic neuropsychotropic effects and mechanisms of action. Pharmateca. 2009;6:28-31. (In Russ.)
  23. Shchepankevich LA, Nikolaev AYu, Dolgova N.A. Optimization lepidoderma therapy in patients with ischemic stroke and diabetes mellitus of the 2nd type. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(2):42-45. (In Russ.)
  24. Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(4):28-31. (In Russ.)
  25. Zhelnov VV, Petrovskaya NV, Komarova IS. Modern approaches to the combined therapy of arterial hypertension. Medical abstract journal. 2007;15(28):2138-2142. (In Russ.)
  26. Belova AN. Scales, tests, questionnaires in neurology and neurosurgery. M.: Antidor; 2004. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.